D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 25 2025
0mins
Should l Buy RGC?
Source: Benzinga
Top Performing Mid-Cap Stocks: D-Wave Quantum Inc. saw a 53.47% increase after launching its Advantage2 quantum system, while Regencell Bioscience Holdings and Advance Auto Parts also experienced significant gains of 42.49% and 38.94%, respectively, following positive company announcements.
Other Notable Stock Increases: Merus N.V. rose by 32.68% due to promising clinical trial data, Oklo Inc. gained 29.56% amid regulatory easing reports, and several other mid-cap stocks like Sibanye-Stillwater Limited and BGM Group Ltd. also showed strong performance last week.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Markets Closed Tuesday with Mixed Results as Paramount Skydance Outperformed and Axon Enterprise Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. ended the day mixed on Tuesday.
- Index Movements: The S&P 500 gained 0.10%, while the Dow Jones rose 0.08%, and the Nasdaq dropped 0.18%.
See More
U.S. Markets Increased on Monday; QXO Saw the Largest Gain
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Monday, with the S&P 500 rising by 1.38%.
- Index Movements: The Dow Jones Industrial Average also increased by 1.38%, while the Nasdaq Composite saw a rise of 1.15%.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Vertex Pharmaceuticals Performance: Vertex Pharmaceuticals Inc. (VRTX) saw a 6.2% increase in pre-market trading.
- UFP Industries Performance: UFP Industries Inc. (UFPI) experienced a 5.0% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Regencell Bioscience Market Risk Analysis
- Staggering Market Capitalization: Regencell Bioscience boasts a market cap nearing $12 billion with a shocking 21,000% stock price increase over the past year, yet investors should exercise caution to avoid being lured by such massive gains.
- Research Stage Risks: As an early-stage bioscience company, Regencell focuses on traditional Chinese medicine (TCM) research, and despite operating for 14 years, it has yet to secure any patented drugs, highlighting the uncertainty and high risks associated with its R&D efforts.
- Lack of Marketable Products: The company's annual report clearly states that Regencell has no saleable products and has not generated any revenue from product sales, raising concerns about its future viability as a going concern.
- Cautious Investment Advice: Given the absence of products and the high-risk nature of its business, investors are advised to steer clear of Regencell and consider established companies like Pfizer that have a robust portfolio of patented drugs to mitigate investment risks.
See More
Regencell Bioscience Faces High-Risk Investment Landscape
- Remarkable Market Capitalization: Regencell Bioscience boasts a market cap nearing $12 billion, with its stock surging 21,000% over the past year, yet investors are advised to tread carefully and not be lured by such massive price gains.
- Lack of Marketable Products: Since its inception in 2014, the company has failed to find any marketable drugs and has not generated revenue from product sales, which significantly heightens the investment risk in the bioscience sector.
- Focus on Traditional Chinese Medicine: Regencell's emphasis on Traditional Chinese Medicine (TCM) lacks the appeal of patented drugs, making it less attractive compared to more established pharmaceutical companies that have proven portfolios.
- Cautious Investment Recommendations: Analysts recommend that investors thoroughly understand the drug candidates being researched by Regencell before considering stock purchases, given the high-risk nature of the investment.
See More
Regencell Bioscience Investment Warning
- Surprising Market Cap: Regencell Bioscience boasts a market capitalization nearing $12 billion, with a staggering 21,000% stock price increase over the past year, yet investors are advised to tread carefully to avoid being lured by such massive gains, given the high-risk nature of the biotech sector.
- Slow R&D Progress: Despite being established in 2014 and focusing on Traditional Chinese Medicine (TCM), Regencell has yet to secure any patented drugs or generate revenue from product sales, highlighting the significant uncertainty surrounding its research outcomes.
- Significant Investment Risks: The lack of marketable products and the focus on TCM render Regencell a high-risk investment, suggesting that most investors should opt for established pharmaceutical companies with a portfolio of patented drugs to mitigate investment risks.
- Market Competition Analysis: Compared to large pharmaceutical firms like Pfizer, Regencell's investment appeal appears minimal, as Pfizer is heavily investing in the GLP-1 space and possesses a robust portfolio of patented drugs to bolster its competitive edge.
See More
U.S. Markets Closed Tuesday with Mixed Results as Paramount Skydance Outperformed and Axon Enterprise Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. ended the day mixed on Tuesday.
- Index Movements: The S&P 500 gained 0.10%, while the Dow Jones rose 0.08%, and the Nasdaq dropped 0.18%.
See More
U.S. Markets Increased on Monday; QXO Saw the Largest Gain
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Monday, with the S&P 500 rising by 1.38%.
- Index Movements: The Dow Jones Industrial Average also increased by 1.38%, while the Nasdaq Composite saw a rise of 1.15%.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Vertex Pharmaceuticals Performance: Vertex Pharmaceuticals Inc. (VRTX) saw a 6.2% increase in pre-market trading.
- UFP Industries Performance: UFP Industries Inc. (UFPI) experienced a 5.0% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Regencell Bioscience Market Risk Analysis
- Staggering Market Capitalization: Regencell Bioscience boasts a market cap nearing $12 billion with a shocking 21,000% stock price increase over the past year, yet investors should exercise caution to avoid being lured by such massive gains.
- Research Stage Risks: As an early-stage bioscience company, Regencell focuses on traditional Chinese medicine (TCM) research, and despite operating for 14 years, it has yet to secure any patented drugs, highlighting the uncertainty and high risks associated with its R&D efforts.
- Lack of Marketable Products: The company's annual report clearly states that Regencell has no saleable products and has not generated any revenue from product sales, raising concerns about its future viability as a going concern.
- Cautious Investment Advice: Given the absence of products and the high-risk nature of its business, investors are advised to steer clear of Regencell and consider established companies like Pfizer that have a robust portfolio of patented drugs to mitigate investment risks.
See More
Regencell Bioscience Faces High-Risk Investment Landscape
- Remarkable Market Capitalization: Regencell Bioscience boasts a market cap nearing $12 billion, with its stock surging 21,000% over the past year, yet investors are advised to tread carefully and not be lured by such massive price gains.
- Lack of Marketable Products: Since its inception in 2014, the company has failed to find any marketable drugs and has not generated revenue from product sales, which significantly heightens the investment risk in the bioscience sector.
- Focus on Traditional Chinese Medicine: Regencell's emphasis on Traditional Chinese Medicine (TCM) lacks the appeal of patented drugs, making it less attractive compared to more established pharmaceutical companies that have proven portfolios.
- Cautious Investment Recommendations: Analysts recommend that investors thoroughly understand the drug candidates being researched by Regencell before considering stock purchases, given the high-risk nature of the investment.
See More
Regencell Bioscience Investment Warning
- Surprising Market Cap: Regencell Bioscience boasts a market capitalization nearing $12 billion, with a staggering 21,000% stock price increase over the past year, yet investors are advised to tread carefully to avoid being lured by such massive gains, given the high-risk nature of the biotech sector.
- Slow R&D Progress: Despite being established in 2014 and focusing on Traditional Chinese Medicine (TCM), Regencell has yet to secure any patented drugs or generate revenue from product sales, highlighting the significant uncertainty surrounding its research outcomes.
- Significant Investment Risks: The lack of marketable products and the focus on TCM render Regencell a high-risk investment, suggesting that most investors should opt for established pharmaceutical companies with a portfolio of patented drugs to mitigate investment risks.
- Market Competition Analysis: Compared to large pharmaceutical firms like Pfizer, Regencell's investment appeal appears minimal, as Pfizer is heavily investing in the GLP-1 space and possesses a robust portfolio of patented drugs to bolster its competitive edge.
See More
